Daclizumab biosimilar - Sunshine Guojian Pharmaceutical

Drug Profile

Daclizumab biosimilar - Sunshine Guojian Pharmaceutical

Alternative Names: Interleukin-2 receptor antagonist - Sunshine Guojian Pharmaceutical; Xenopax

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Shanghai CP Guojian Pharmaceutical
  • Developer Sunshine Guojian Pharmaceutical
  • Class Monoclonal antibodies
  • Mechanism of Action Interleukin 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Renal transplant rejection
  • No development reported Multiple sclerosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Multiple-sclerosis in China (IV, Injection)
  • 01 Jan 2012 Clinical trials in Multiple sclerosis in China (IV)
  • 31 Dec 2011 Launched for Rheumatoid arthritis (prevention) in China (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top